EP1784639A4 - Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes - Google Patents

Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes

Info

Publication number
EP1784639A4
EP1784639A4 EP05784165A EP05784165A EP1784639A4 EP 1784639 A4 EP1784639 A4 EP 1784639A4 EP 05784165 A EP05784165 A EP 05784165A EP 05784165 A EP05784165 A EP 05784165A EP 1784639 A4 EP1784639 A4 EP 1784639A4
Authority
EP
European Patent Office
Prior art keywords
freeze
methods
dried platelets
platelets
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05784165A
Other languages
German (de)
English (en)
Other versions
EP1784639B1 (fr
EP1784639A2 (fr
Inventor
David Ho
Cindy S Orser
Alan S Rudolph
Keith A Moskowitz
Joshua Dee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellphire Inc
Original Assignee
Cellphire Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/152,774 external-priority patent/US20060035383A1/en
Priority claimed from US11/197,310 external-priority patent/US20060051731A1/en
Application filed by Cellphire Inc filed Critical Cellphire Inc
Publication of EP1784639A2 publication Critical patent/EP1784639A2/fr
Publication of EP1784639A4 publication Critical patent/EP1784639A4/fr
Application granted granted Critical
Publication of EP1784639B1 publication Critical patent/EP1784639B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0278—Physical preservation processes
    • A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05784165A 2004-08-12 2005-08-12 Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes Active EP1784639B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60083804P 2004-08-12 2004-08-12
US61993004P 2004-10-20 2004-10-20
US11/152,774 US20060035383A1 (en) 2004-08-12 2005-06-15 Dry platelet preparations for use in diagnostics
US11/197,310 US20060051731A1 (en) 2004-08-12 2005-08-05 Processes for preparing lyophilized platelets
PCT/US2005/028559 WO2006020773A2 (fr) 2004-08-12 2005-08-12 Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes

Publications (3)

Publication Number Publication Date
EP1784639A2 EP1784639A2 (fr) 2007-05-16
EP1784639A4 true EP1784639A4 (fr) 2008-05-07
EP1784639B1 EP1784639B1 (fr) 2010-01-20

Family

ID=35908143

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05784165A Active EP1784639B1 (fr) 2004-08-12 2005-08-12 Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes

Country Status (10)

Country Link
US (1) US8486617B2 (fr)
EP (1) EP1784639B1 (fr)
JP (1) JP5138372B2 (fr)
CN (1) CN101072506B (fr)
AT (1) ATE455463T1 (fr)
AU (1) AU2005272821B2 (fr)
CA (1) CA2577068C (fr)
DE (1) DE602005019064D1 (fr)
NZ (1) NZ553389A (fr)
WO (1) WO2006020773A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006294654B2 (en) * 2005-09-26 2012-05-24 Lifecell Corporation Dry platelet composition
US8058064B2 (en) * 2006-10-04 2011-11-15 The University Of Tokyo Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells
US8372343B2 (en) * 2007-12-07 2013-02-12 Sheldon Goldstein Multiple coagulation test cartridge and method of using same
WO2010022202A1 (fr) * 2008-08-20 2010-02-25 Bio/Data Corporation Analyses d'activité biologique cinétique et analyse cinétique de facteur willebrand
JP2013524784A (ja) * 2010-04-08 2013-06-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血小板の保存のためのゼオドレーション法
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
CN101957364A (zh) * 2010-09-19 2011-01-26 李勇 冻干型血小板抗原谱细胞的制备方法
WO2012098358A1 (fr) * 2011-01-20 2012-07-26 Biopharma Technology Ltd Procédé de lyophilisation
GB201101002D0 (en) * 2011-01-20 2011-03-09 Biopharma Technology Ltd Freeze drying method
EP2508892A1 (fr) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Contrôles et kit pour tests d'activité des thrombocytes
CN102327288B (zh) * 2011-10-17 2012-11-14 济南环肽医药科技有限公司 一种注射用血小板冻干粉制剂及其制备方法
EP2934572A4 (fr) 2012-12-20 2016-11-23 Biomatrica Inc Formulations et procédés pour stabiliser des réactifs pcr
AU2013204728B2 (en) * 2013-03-15 2016-09-15 Baxalta GmbH Methods for treating bleeding disorders using a platelet subpopulation
BR112015021343A2 (pt) 2013-03-15 2017-07-18 Cook Biotech Inc composições e métodos de implante de ecm
TW201446253A (zh) * 2013-06-07 2014-12-16 Chang Gung Medical Foundation Lin Kou Chang Gung Memorial Hospital 非凝集預活變形血小板之應用及其藥劑
EP3154338B1 (fr) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilisation de thrombocytes à des températures ambiantes
WO2016022433A1 (fr) * 2014-08-07 2016-02-11 The General Hospital Corporation Stabilisation d'échantillons de sang total
JP2018504395A (ja) * 2014-12-31 2018-02-15 アンソロジェネシス コーポレーションＡｎｔｈｒｏｇｅｎｅｓｉｓ Ｃｏｒｐｏｒａｔｉｏｎ 血小板の分離方法
WO2016141325A1 (fr) * 2015-03-04 2016-09-09 University Of Rochester Application topique et systémique de microparticules plaquettaires pour traiter le saignement chez des patients souffrant d'un traumatisme
EP3307283B1 (fr) * 2015-06-10 2020-09-02 Cellphire Inc. Composition et procédés pour le traitement de la perte de fluides conduisant à l'hypotension et/ou l'hypovolémie
WO2017040238A1 (fr) * 2015-08-28 2017-03-09 Cellphire, Inc. Produits et méthodes d'utilisation d'un agent hémostatique dérivé des plaquettes pour la régulation du saignement et l'amélioration de la cicatrisation
EP4242628A3 (fr) 2015-12-08 2023-11-08 Biomatrica, INC. Réduction de vitesse de sédimentation des érythrocytes
US20190041379A1 (en) * 2016-02-10 2019-02-07 Sony Corporation Sample for measurement of electric characteristics, electric characteristic measuring apparatus, and electric characteristic measuring method
CA3046455A1 (fr) * 2016-12-08 2018-06-14 Cellphire, Inc. Composition et methodes pour le traitement de perte de fluides conduisant a l'hypotension et/ou l'hypovolemie
WO2018112780A1 (fr) * 2016-12-21 2018-06-28 Chung Chin Sun Nouveau procédé de conservation de l'activité des protéines du plasma sanguin
US20190076478A1 (en) * 2017-09-13 2019-03-14 Cellphire, Inc. Canine blood platelet preparations
CN107998375B (zh) * 2017-12-14 2021-11-05 广东医科大学 一种多肽在预防或治疗血栓性疾病或脑缺血再灌注损伤相关疾病中的应用
EP3886879A4 (fr) 2018-11-30 2022-12-07 Cellphire Inc. Plaquettes en tant qu'agents de livraison
US20200208110A1 (en) * 2018-11-30 2020-07-02 Cellphire, Inc. PLATELETS LOADED WITH mRNA
WO2020186193A1 (fr) * 2019-03-13 2020-09-17 Cellphire, Inc. Préparations de plaquettes sanguines canines
US10429377B1 (en) 2019-03-15 2019-10-01 Coagulation Sciences Llc Coagulation test device, system, and method of use
AU2020267368B2 (en) 2019-05-03 2023-05-04 Cellphire, Inc. Materials and methods for producing blood products
US20210100846A1 (en) * 2019-07-17 2021-04-08 Cellphire, Inc. Use of platelets in treating infections
JP2022544788A (ja) * 2019-08-16 2022-10-21 セルフィアー インコーポレイテッド 抗凝固剤拮抗剤としてのトロンボソーム
US11701388B2 (en) * 2019-08-16 2023-07-18 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CN110585240B (zh) * 2019-10-10 2021-10-29 石开生物科技(广州)有限公司 一种含再生因子的冻干制剂及其制备方法和应用
WO2021108538A1 (fr) * 2019-11-27 2021-06-03 Cellphire, Inc. Plaquettes chargées d'arnm
WO2021158645A1 (fr) 2020-02-04 2021-08-12 Cellphire, Inc. Procédés de traitement de l'hémophilie congénitale avec des plaquettes chargées d'un anti-fibrinolytique
WO2021232015A1 (fr) 2020-05-15 2021-11-18 Cellphire, Inc. Vésicules extracellulaires dérivées de plaquettes
CN113156144A (zh) * 2021-01-29 2021-07-23 郑州普湾医疗技术有限公司 一种血小板聚集功能花生四烯酸杯检测试剂及其制备方法
WO2022178177A1 (fr) 2021-02-17 2022-08-25 Cellphire, Inc. Compositions de dérivé de plaquettes lyophilisées pour le traitement de la coagulopathie induite par les plaquettes
WO2022178191A1 (fr) 2021-02-17 2022-08-25 Cellphire, Inc. Compositions lyophilisées de dérivés de plaquettes pour le traitement de la coagulopathie induite par les anticoagulants
EP4086634A1 (fr) * 2021-05-06 2022-11-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Procédé pour diagnostiquer une prédisposition d'un être vivant pour développer une thrombocytopénie
WO2023081804A1 (fr) 2021-11-04 2023-05-11 Cellphire, Inc. Compositions de dérivés de plaquettes et leurs méthodes de production et d'utilisation
WO2023220694A1 (fr) 2022-05-12 2023-11-16 Cellphire, Inc. Compositions de plaquettes chargées d'agent d'irm et leurs procédés de préparation et d'utilisation
WO2023220739A1 (fr) 2022-05-12 2023-11-16 Cellphire, Inc. Compositions dérivées de plaquettes destinées à être utilisées chez des sujets atteints d'un syndrome de hermansky pudlak ou d'un syndrome de bernard soulier
CN117180441A (zh) * 2023-10-11 2023-12-08 北京朴汇细胞生物科技有限公司 一种血小板脱水干燥保护剂、血小板脱水干燥制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736313A (en) * 1995-10-20 1998-04-07 The United States Of America As Represented By The Secretary Of The Navy Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing
US6221575B1 (en) * 1997-02-07 2001-04-24 Quadrant Holdings Cambridge Ltd. Methods for producing dried storage-stable platelets and compositions obtained thereby

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213814A (en) 1989-04-10 1993-05-25 Cryopharm Corporation Lyophilized and reconstituted blood platelet compositions
ES2194013T3 (es) 1992-05-29 2003-11-16 Univ North Carolina Plaquetas de sangre humana de secado fijo farmaceuticamente aceptables.
EP0668013B1 (fr) 1994-02-22 2005-04-20 Nippon Telegraph And Telephone Corporation Globules sanguines, cellules souches et plaquettes lyophilisées et leur procédé de préparation
JP3788522B2 (ja) * 1994-02-22 2006-06-21 日本電信電話株式会社 血球、幹細胞、および血小板の凍結乾燥生成物の製造方法
JPH09109136A (ja) 1995-10-16 1997-04-28 Mitsubishi Materials Corp モルタル又はコンクリートの製造装置
EP1015826A2 (fr) 1996-05-29 2000-07-05 Universal Preservation Technologies, Inc. Accroissement de la duree de conservation par vitrification
US6211575B1 (en) * 1999-08-18 2001-04-03 Sigmatel Inc. Method and apparatus for identifying customized integrated circuits
US20020076445A1 (en) 2000-02-10 2002-06-20 Crowe John H. Eukaryotic cells and method for preserving cells
AU2001234978A1 (en) 2000-02-10 2001-08-20 The Regents Of The University Of California Therapeutic platelets and methods
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1404376B1 (fr) 2000-10-19 2009-10-14 Bracco Imaging SPA Formulations de produits radiopharmaceutiques
AU2003302323A1 (en) 2002-11-29 2004-06-23 The Regents Of The University Of California A method and therapeutic platelets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736313A (en) * 1995-10-20 1998-04-07 The United States Of America As Represented By The Secretary Of The Navy Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing
US6221575B1 (en) * 1997-02-07 2001-04-24 Quadrant Holdings Cambridge Ltd. Methods for producing dried storage-stable platelets and compositions obtained thereby

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOLKERS W F ET AL: "HUMAN PLATELETS LOADED WITH TREHALOSE SURVIVE FREEZE-DRYING", CRYOBIOLOGY, ACADEMIC PRESS INC, US, vol. 42, no. 2, 2001, pages 79 - 87, XP001183459, ISSN: 0011-2240 *

Also Published As

Publication number Publication date
WO2006020773A2 (fr) 2006-02-23
CA2577068C (fr) 2016-05-17
AU2005272821B2 (en) 2010-09-09
AU2005272821A1 (en) 2006-02-23
CN101072506A (zh) 2007-11-14
NZ553389A (en) 2009-10-30
ATE455463T1 (de) 2010-02-15
CN101072506B (zh) 2010-05-12
DE602005019064D1 (de) 2010-03-11
WO2006020773A3 (fr) 2007-07-12
EP1784639B1 (fr) 2010-01-20
EP1784639A2 (fr) 2007-05-16
JP5138372B2 (ja) 2013-02-06
JP2008509924A (ja) 2008-04-03
US20070243178A1 (en) 2007-10-18
US8486617B2 (en) 2013-07-16
CA2577068A1 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1784639A4 (fr) Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
IL214325A (en) Antibody against cmet, a drug that includes and uses it
TW200716646A (en) (S)-N-methylnaltrexone
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
HK1109638A1 (en) Dr5 antibodies and uses thereof dr5
SG164368A1 (en) Treatment of cancer
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2006031926A3 (fr) Procedes d'isolation et d'expansion de lymphocytes t regulateurs derives du sang du cordon ombilical
TW200716088A (en) Formulations and methods for treating amyloidosis
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
EP2277918A3 (fr) Antigène peptide mhc classe I et II dérivé d'une tumeur antigène 5t4
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070312

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20070712

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 63/00 20060101AFI20070829BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLPHIRE, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080409

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/86 20060101ALI20080403BHEP

Ipc: A61K 35/14 20060101ALI20080403BHEP

Ipc: A01N 63/00 20060101AFI20070829BHEP

17Q First examination report despatched

Effective date: 20080718

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DEE, JOSHUA

Inventor name: MOSKOWITZ, KEITH, A.

Inventor name: RUDOLPH, ALAN, S.

Inventor name: ORSER, CINDY, S.

Inventor name: HO, DAVID

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005019064

Country of ref document: DE

Date of ref document: 20100311

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100520

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100520

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100421

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100420

26N No opposition filed

Effective date: 20101021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: CELLPHIRE, INC.

Free format text: CELLPHIRE, INC.#9430 KEY WEST AVENUE, SUITE 104#ROCKVILLE, MD 20850 (US) -TRANSFER TO- CELLPHIRE, INC.#9430 KEY WEST AVENUE, SUITE 104#ROCKVILLE, MD 20850 (US)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100812

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005019064

Country of ref document: DE

Representative=s name: CBDL PATENTANWAELTE GBR, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230826

Year of fee payment: 19

Ref country code: LU

Payment date: 20230828

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20230720

Year of fee payment: 19

Ref country code: GB

Payment date: 20230828

Year of fee payment: 19

Ref country code: CH

Payment date: 20230903

Year of fee payment: 19

Ref country code: AT

Payment date: 20230719

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230825

Year of fee payment: 19

Ref country code: DE

Payment date: 20230829

Year of fee payment: 19